Economic Burden of Asthma in Northwest Iran.
Asthma
Cost of illness
Economic burden
Socioeconomic factors
Work performance
Journal
Iranian journal of medical sciences
ISSN: 1735-3688
Titre abrégé: Iran J Med Sci
Pays: Iran
ID NLM: 8104374
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
25
08
2021
revised:
24
12
2021
accepted:
31
01
2022
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
14
3
2023
Statut:
ppublish
Résumé
The economic burden of asthma is a major public health concern. This study estimates the economic burden of asthma in Northwest of Iran. A longitudinal study was conducted between 2017 and 2018 in Tabriz (Iran) using the Persian version of the Work Productivity and Activity Impairment (WPAI) questionnaire. Direct and indirect costs associated with asthma were estimated based on the societal perspective, prevalence-based approach, and bottom-up method. Annual indirect costs were estimated using the human capital (HC) method. The structural equation model was used to evaluate the relationship between costs, sex, and asthma severity. A total of 621 patients with asthma were enrolled in the study. Significant differences were found between female and male patients for the mean cost of radiology (P=0.006), laboratory (P=0.028), and diagnostic (P=0.017) tests at baseline, and for laboratory (P=0.012), and diagnostic (P=0.027) tests at one-year follow-up. The more severe asthma, the more significant the costs for annual physician office visits (P=0.040) and medications (P=0.013). As asthma severity increased, significantly higher expenditures were observed in women for days lost from work at baseline (P=0.009) and one-year follow-up (P=0.001), and in men for productivity loss at work due to impairment at baseline (P=0.045). A significant association between indirect costs and the cost of impairment-related lost productivity at work (β=3.29, P<0.001), and between severe asthma and indirect costs (β=32.36, P<0.001) was observed. High costs are incurred by Iranian asthma patients, especially because of impairment-related productivity loss at work associated with asthma exacerbation.
Sections du résumé
Background
The economic burden of asthma is a major public health concern. This study estimates the economic burden of asthma in Northwest of Iran.
Methods
A longitudinal study was conducted between 2017 and 2018 in Tabriz (Iran) using the Persian version of the Work Productivity and Activity Impairment (WPAI) questionnaire. Direct and indirect costs associated with asthma were estimated based on the societal perspective, prevalence-based approach, and bottom-up method. Annual indirect costs were estimated using the human capital (HC) method. The structural equation model was used to evaluate the relationship between costs, sex, and asthma severity.
Results
A total of 621 patients with asthma were enrolled in the study. Significant differences were found between female and male patients for the mean cost of radiology (P=0.006), laboratory (P=0.028), and diagnostic (P=0.017) tests at baseline, and for laboratory (P=0.012), and diagnostic (P=0.027) tests at one-year follow-up. The more severe asthma, the more significant the costs for annual physician office visits (P=0.040) and medications (P=0.013). As asthma severity increased, significantly higher expenditures were observed in women for days lost from work at baseline (P=0.009) and one-year follow-up (P=0.001), and in men for productivity loss at work due to impairment at baseline (P=0.045). A significant association between indirect costs and the cost of impairment-related lost productivity at work (β=3.29, P<0.001), and between severe asthma and indirect costs (β=32.36, P<0.001) was observed.
Conclusion
High costs are incurred by Iranian asthma patients, especially because of impairment-related productivity loss at work associated with asthma exacerbation.
Identifiants
pubmed: 36895455
doi: 10.30476/IJMS.2022.92421.2373
pii: IJMS-48-2
pmc: PMC9989240
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
156-166Informations de copyright
Copyright: © Iranian Journal of Medical Sciences.
Déclaration de conflit d'intérêts
None declared.
Références
Arch Iran Med. 2014 Dec;17(12):804-9
pubmed: 25481318
Ann Allergy Asthma Immunol. 2019 Dec;123(6):564-572.e3
pubmed: 31494235
BMC Pulm Med. 2009 May 19;9:24
pubmed: 19454036
J Asthma. 2021 Feb;58(2):207-212
pubmed: 31621441
Iran J Public Health. 2018 Feb;47(2):256-263
pubmed: 29445636
J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138
pubmed: 17983880
Iran J Allergy Asthma Immunol. 2018 Dec 03;17(6):601-603
pubmed: 30644705
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Psychometrika. 2011 Oct;76(4):511-36
pubmed: 27519679
Pharmacol Res. 2017 May;119:384-390
pubmed: 28238829
Clin Mol Hepatol. 2014 Dec;20(4):327-37
pubmed: 25548737
Value Health. 2008 Mar-Apr;11(2):231-9
pubmed: 18380635
BMJ Open Respir Res. 2020 Mar;7(1):
pubmed: 32193226
J Med Econ. 2015 Jun;18(6):457-65
pubmed: 25660324
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1102-1112
pubmed: 31166782
Iran J Public Health. 2015 Sep;44(9):1212-8
pubmed: 26587495
Farm Hosp. 2020 Apr 14;44(3):109-113
pubmed: 32452310
Ann Am Thorac Soc. 2018 Mar;15(3):348-356
pubmed: 29323930
Psychol Methods. 2010 Dec;15(4):309-34
pubmed: 20954780
Expert Rev Respir Med. 2020 Jul;14(7):757-762
pubmed: 32233706
Lancet. 2016 Oct 8;388(10053):1603-1658
pubmed: 27733283
J Appl Psychol. 2019 Nov;104(11):1404-1433
pubmed: 31045381
Clin Respir J. 2018 May;12(5):1872-1881
pubmed: 29227026
Risk Manag Healthc Policy. 2020 Jul 31;13:969-978
pubmed: 32801971
Appl Health Econ Health Policy. 2019 Oct;17(5):629-640
pubmed: 30997609
J Med Econ. 2020 May;23(5):492-500
pubmed: 31958257
BMC Med. 2016 Aug 29;14(1):113
pubmed: 27568881
J Allergy Clin Immunol. 2002 Feb;109(2):264-70
pubmed: 11842295